These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11907492)

  • 21. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.
    Quinn MJ; Bhatt DL; Zidar F; Vivekananthan D; Chew DP; Ellis SG; Plow E; Topol EJ
    Am J Cardiol; 2004 Mar; 93(6):679-84. PubMed ID: 15019868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
    Massberg S; Mueller I; Besta F; Thomas P; Gawaz M
    Am Heart J; 2003 Nov; 146(5):E19. PubMed ID: 14597948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.
    Xiao Z; Théroux P
    J Am Coll Cardiol; 2004 Jun; 43(11):1982-8. PubMed ID: 15172401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Sabaté M; Fernández C; Stranieri C; Trabetti E; Pignatti PF; Macaya C
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):89-93. PubMed ID: 15166949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
    Bliden KP; Dichiara J; Lawal L; Singla A; Antonino MJ; Baker BA; Bailey WL; Tantry US; Gurbel PA
    J Am Coll Cardiol; 2008 Aug; 52(7):531-3. PubMed ID: 18687246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
    Graff J; Andries D; Elsner M; Westrup D; Bassus S; Franz N; Klinkhardt U; Harder S
    Br J Clin Pharmacol; 2001 Jun; 51(6):577-82. PubMed ID: 11422017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
    Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
    Graff J; Klinkhardt U; Harder S
    Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet glycoprotein IIb/IIIa receptor antagonist (abciximab) inhibited platelet activation and promoted skin flap survival after ischemia/reperfusion injury.
    Kuo YR; Jeng SF; Wang FS; Huang HC; Wei FC; Yang KD
    J Surg Res; 2002 Sep; 107(1):50-5. PubMed ID: 12384064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
    Storey RF; Judge HM; Wilcox RG; Heptinstall S
    Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728.
    Tsao PW; Forsythe MS; Mousa SA
    Thromb Res; 1997 Oct; 88(2):137-46. PubMed ID: 9361367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P-selectin (CD62p) and P-selectin glycoprotein ligand-1 (PSGL-1) polymorphisms: minor phenotypic differences in the formation of platelet-leukocyte aggregates and response to clopidogrel.
    Klinkhardt U; Dragutinovic I; Harder S
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):255-63. PubMed ID: 15968882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting.
    Antonino MJ; Mahla E; Bliden KP; Tantry US; Gurbel PA
    Am J Cardiol; 2009 Jun; 103(11):1546-50. PubMed ID: 19463513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty.
    Fredrickson BJ; Turner NA; Kleiman NS; Graziadei N; Maresh K; Mascelli MA; Effron MB; McIntire LV
    Circulation; 2000 Mar; 101(10):1122-9. PubMed ID: 10715258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.